Cambium Bio (ASX:CMB) Buyback Yield %: -39.04 (As of Jun. 29, 2026)


ASX:CMB Cambium Bio Ltd ASX:CMB
35 GF Score
Price A$0.42
! 4 Warning Signs
View Full Analysis

What is Cambium Bio Buyback Yield %?

Cambium Bio ASX:CMB +1.20% 35 Buyback Yield % is -39.04 as of Jun. 29, 2026. GuruFocus rates ASX:CMB with a GF Score™ of 35/100. The stock has 4 warning signs investors should review. Among 742 Biotechnology companies, Cambium Bio ranks worse than 80.19% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Cambium Bio's current buyback yield was -39.04%.

Cambium Bio Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Cambium Bio's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cambium Bio Buyback Yield % Chart

Cambium Bio Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.68 0.00 1.45 -58.35 -75.04

Cambium Bio Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -58.35 -11.78 -75.04 -41.02

ASX:CMB vs VRTX, REGN, ALNY: Buyback Yield % Comparison

For the Biotechnology subindustry, Cambium Bio's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cambium Bio Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Cambium Bio's Buyback Yield % falls into.


ASX:CMB
35GF Score
Cambium Bio Ltd ASX:CMB
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cambium Bio Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Cambium Bio's Buyback Yield for the fiscal year that ended in Jun. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 2.881) / 3.83943
=-75.04%

Cambium Bio's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 4.428) / 10.79496
=-41.02%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -39.04 mean?
Cambium Bio (ASX:CMB) has a Buyback Yield % of -39.04 as of Jun. 29, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cambium Bio and its competitors. According to the industry distribution chart, Cambium Bio ranks #595 out of 742 companies in the Biotechnology industry, placing it in the top 80.2%.
Is Cambium Bio's Buyback Yield % too high?
Cambium Bio's current Buyback Yield % is -39.04. Based on the distribution chart, Cambium Bio ranks #595 out of 742 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cambium Bio has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cambium Bio ranks #595 out of 742 companies for Buyback Yield %. This places Cambium Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cambium Bio and its competitors. Cambium Bio's current Buyback Yield % is -39.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current Buyback Yield % of -39.04. The current Buyback Yield % is -39.04. Cambium Bio's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current Buyback Yield % is -39.04 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambium Bio Business Description

Address Unit 2.06, 31 Lexington Drive, Bella Vista, NSW, AUS, 2153
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
35GF Score

Get the complete analysis for ASX:CMB

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.42
Price